 Inozyme Pharma Inc NASDAQ: INZY announced preliminary biomarker, safety, and pharmacokinetic PK data from the first three patients treated in the Phase 1 portion of its Phase 12 trial of INZ-701 in ENPP1 Deficiency. ENPP1 Deficiency manifests generalized arterial. 